Oncology, December 13th, 2007
Reporting from: San Antonio Breast Cancer Symposium, 13-16 December, 2007
Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
STEPHEN JONES, US Oncology Research, Houston
REFERENCE: ABSTRACT 12
Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. As Stephen Jones of US Oncology Research explained to Derek Thorne, this advantage was also seen in patients over 65.
